Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 195

Showing 1-25 of 195 citing articles:

Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Rana Mhaidly, Fatima Mechta‐Grigoriou
Seminars in Immunology (2020) Vol. 48, pp. 101417-101417
Open Access | Times Cited: 202
Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer
Rana Mhaidly, Fatima Mechta‐Grigoriou
Immunological Reviews (2021) Vol. 302, Iss. 1, pp. 259-272
Open Access | Times Cited: 159
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Mélanie Desbois, Yulei Wang
Immunological Reviews (2021) Vol. 302, Iss. 1, pp. 241-258
Closed Access | Times Cited: 137
Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
Song Li, Wenbin Yu, Fei Xie, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 127
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Liangliang Xu, Chang Zou, Shanshan Zhang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 112
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer
Isabel Heidegger, Georgios Fotakis, Anne Offermann, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 68
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1143-1143
Open Access | Times Cited: 46
Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
Shengnan Ren, Lingxin Feng, Haoran Liu, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 14, pp. 1149-1163
Open Access | Times Cited: 17
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures
Florent Peyraud, Jean-Philippe Guégan, Christophe Rey, et al.
Cell Reports Medicine (2025), pp. 101934-101934
Open Access | Times Cited: 1
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Wan Du, Timothy L. Frankel, Michael Green, et al.
Cellular and Molecular Immunology (2021) Vol. 19, Iss. 1, pp. 23-32
Open Access | Times Cited: 93
Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer
Maoyu Xiao, Jun He, Liyang Yin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 70
Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
Yingying He, Tao Liu, Shuang Dai, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 55
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
Xiaoting Zhou, Yanghong Ni, Xiao Liang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
The Landscape of Immunotherapy Resistance in NSCLC
Daniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 43
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 34
An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms
Nan Zhang, Hao Zhang, Zaoqu Liu, et al.
Cell Proliferation (2023) Vol. 56, Iss. 4
Open Access | Times Cited: 33
Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC
Wenjing Liu, Lin Wang, Feng-Mei Zhou, et al.
Drug Resistance Updates (2023) Vol. 70, pp. 100987-100987
Open Access | Times Cited: 29
Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer
Edwin R. Parra, Jiexin Zhang, Mei Jiang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
Alejandro Olivares-Hernández, Elisabet González-Del Portillo, Álvaro Tamayo-Velasco, et al.
Annals of Translational Medicine (2023) Vol. 11, Iss. 10, pp. 354-354
Open Access | Times Cited: 24
Single‐cell and spatial transcriptomics reveal POSTN+ cancer‐associated fibroblasts correlated with immune suppression and tumour progression in non‐small cell lung cancer
Chao Chen, Qiang Guo, Yang Liu, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 12
Open Access | Times Cited: 24
Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer
Tanmoy Saha, Michaela Fojtů, Astha Vinay Nagar, et al.
Science Advances (2024) Vol. 10, Iss. 24
Open Access | Times Cited: 13
Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
Andreas Domen, Delphine Quatannens, Sara Zanivan, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 50
Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
Minglei Yang, Cheng-Hao Lin, Yanni Wang, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 37
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly‐Khan A. Lalani, Caroline Robert, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003024-e003024
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top